# IFRX catalysts: InflaRx N.V. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ifrx/catalysts

> InflaRx N.V. (IFRX) has 2 upcoming catalysts. The next is the GOHIBIC (vilobelimab) interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IFRX?

InflaRx N.V. (IFRX) has 2 upcoming catalysts. The next is the GOHIBIC (vilobelimab) interim data readout, 2027. Press release filed with the SEC (EX-99): "InflaRx is currently in the planning stages for this development effort, with a goal of generating initial data from these open-label proof-of-concept studies in 2027." [Calendar and source filings](https://sec-api.dev/companies/ifrx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001140361-26-031540, https://www.sec.gov/Archives/edgar/data/1708688/000114036126031540/ef20079015_ex99-3.htm (retrieved 2026-11-12). Last confirmed 2026-08-06. Cite: https://sec-api.dev/companies/ifrx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | InflaRx N.V. |
| Ticker | IFRX (Nasdaq) |
| SEC CIK | 1708688 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ifrx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2023 | [GOHIBIC (vilobelimab) trial start](https://sec-api.dev/pdufa/vilobelimab) | IFRX |  | completed | "These include PG, a chronic inflammatory skin disorder for which we started a Phase 3 study with the first patient treated in November 2023, the treatment of critically ill COVID-19 patients, for which we concluded a Phase 3 study in March 2022 and subsequently were granted the EUA by the FDA in April 2023, and marketing authorization, under exceptional circumstances, by the European Commission in January 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1708688/000121390025025292/ea0234504-20f_inflarxnv.htm)) |
| December 20, 2024 | [Izicopan trial start](https://sec-api.dev/pdufa/izicopan) | IFRX |  | completed | "InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036124050007/ef20040227_ex99-1.htm)) |
| 2025 | [GOHIBIC (vilobelimab) NDA/BLA submission](https://sec-api.dev/pdufa/vilobelimab) | IFRX |  | scheduled | "We expect our expenses associated with vilobelimab to increase in 2025 compared to 2024, as we continue discussions with the FDA related to the planned submission of a BLA for full approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036125017620/ef20048286_ex99-2.htm)) |
| May 2025 | [GOHIBIC (vilobelimab) interim data readout](https://sec-api.dev/pdufa/vilobelimab) | IFRX |  | scheduled | "Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036125009582/ef20045567_ex99-1.htm)) |
| May 2025 | [InflaRx N.V. interim data readout](https://sec-api.dev/companies/ifrx/catalysts) | IFRX |  | scheduled | "March 2025, we announced that the Phase 3 blinded interim analysis is expected by the end of May 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1708688/000121390025025292/ea0234504-20f_inflarxnv.htm)) |
| Jun 2025 | [GOHIBIC (vilobelimab) interim data readout](https://sec-api.dev/pdufa/vilobelimab) | IFRX |  | scheduled | "Vilobelimab in PG - Announcement on pivotal Phase 3 interim analysis expected at end of May to early June 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036125017620/ef20048286_ex99-3.htm)) |
| July 11, 2025 | [GOHIBIC (vilobelimab) primary completion](https://sec-api.dev/pdufa/vilobelimab) | IFRX | Pyoderma Gangrenosum | withdrawn | "NCT05964413 (Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor InflaRx GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05964413)) |
| late 2025 | [GOHIBIC (vilobelimab) topline data readout](https://sec-api.dev/pdufa/vilobelimab) | IFRX |  | scheduled | "Topline data from this study are expected in the summer of 2025, with a goal of informing the planning and design of a larger, longer-term Phase 2b study by year-end 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036125009582/ef20045567_ex99-1.htm)) |
| Nov 2025 | [Izicopan topline data readout](https://sec-api.dev/pdufa/izicopan) | IFRX |  | completed, positive | "In November 2025, InflaRx announced positive topline data from a Phase 2a basket study exploring izicopan in HS and chronic spontaneous urticaria (CSU)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000121390026031549/ea028182101ex99-1.htm)) |
| January 22, 2026 | [Csu lower dose treatment primary completion](https://sec-api.dev/pdufa/csu-lower) | IFRX | Chronic Urticaria, Idiopathic; Hidradenitis; Hidradenitis Suppurativa | withdrawn | "NCT06555328 (Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-01-22 (ACTUAL); Lead Sponsor InflaRx GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06555328)) |
| 2027 | [GOHIBIC (vilobelimab) interim data readout](https://sec-api.dev/pdufa/vilobelimab) | IFRX |  | scheduled | "InflaRx is currently in the planning stages for this development effort, with a goal of generating initial data from these open-label proof-of-concept studies in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036126031540/ef20079015_ex99-3.htm)) |
| 2H 2027 | [Izicopan interim data readout](https://sec-api.dev/pdufa/izicopan) | IFRX | renal vasculitis | scheduled | "Today's takeaways Izicopan has potential to expand the AAV market, with multiple differentiating features that could drive a $1.5B - $2B peak sales potential Izicopan AAV development program is primed for generating differentiated efficacy and safety data placebo-controlled study in patients with renal vasculitis (i.e., renal involvement) assessing izicopan's ability to drive signals of efficacy over the standard of care open-label study in "all-comers" to demonstrate the ability to replace corticosteroids Additional studies in rare renal disease targeted for initiation in 2027 include aHUS, with initial data targeted for 2H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708688/000114036126041828/ef20054802_ex99-2.htm)) |

## Drugs

- [Csu lower dose treatment](https://sec-api.dev/pdufa/csu-lower): Chronic Urticaria, Idiopathic
- [Izicopan](https://sec-api.dev/pdufa/izicopan): renal vasculitis
- [GOHIBIC (vilobelimab)](https://sec-api.dev/pdufa/vilobelimab): Pyoderma Gangrenosum

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ifrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IFRX catalysts: InflaRx N.V. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ifrx/catalysts

```bibtex
@misc{secapidev_companies_ifrx_catalysts_20261116,
  title        = {IFRX catalysts: InflaRx N.V. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ifrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ifrx_catalysts_20261116","title":"IFRX catalysts: InflaRx N.V. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ifrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
